Search research articles
Contact Us
Filters
Showing results (21-30 of 44) with videos related to
Page
of 5
Sort By:
Cancer Medicine
|
May 13, 2016
Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy
Nicholas R Latimer, Helen Bell, Keith R Abrams, et al.
Pharmacoeconomics
|
July 26, 2014
Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal
Nicholas R Latimer, Christopher Carroll, Ruth Wong, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 20, 2023
Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause Survival
Sangyu Lee, Paul C Lambert, Michael J Sweeting, et al.
The Oncologist
|
June 5, 2015
Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine
Nicholas R Latimer, Keith R Abrams, Mayur M Amonkar, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
December 28, 2023
Perils of Randomized Controlled Trial Survival Extrapolation Assuming Treatment Effect Waning: Why the Distinction Between Marginal and Conditional Estimates Matters
Angus C Jennings, Mark J Rutherford, Nicholas R Latimer, et al.
Statistical Methods in Medical Research
|
April 27, 2016
Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study
Nicholas R Latimer, Keith R Abrams, Paul C Lambert, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 7, 2019
Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study
Helen Bell Gorrod, Nicholas R Latimer, Doris Damian, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 22, 2020
Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting
Thomas R Sullivan, Nicholas R Latimer, Jodi Gray, et al.
Advances in Therapy
|
November 9, 2019
Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods
Helen Bell Gorrod, Nicholas R Latimer, Doris Damian, et al.
MDM Policy & Practice
|
June 15, 2026
Evaluating the Impact of Different Natural History Modeling Methods on Cost-Effectiveness Decisions: A Case Study in Duchenne Muscular Dystrophy
Jonathan Broomfield, Keith R Abrams, Michael J Crowther, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 44) with videos related to
Sort By:
Page
of 5
Cancer Medicine
|
May 13, 2016
Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy
Nicholas R Latimer, Helen Bell, Keith R Abrams, et al.
Pharmacoeconomics
|
July 26, 2014
Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal
Nicholas R Latimer, Christopher Carroll, Ruth Wong, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 20, 2023
Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause Survival
Sangyu Lee, Paul C Lambert, Michael J Sweeting, et al.
The Oncologist
|
June 5, 2015
Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine
Nicholas R Latimer, Keith R Abrams, Mayur M Amonkar, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
December 28, 2023
Perils of Randomized Controlled Trial Survival Extrapolation Assuming Treatment Effect Waning: Why the Distinction Between Marginal and Conditional Estimates Matters
Angus C Jennings, Mark J Rutherford, Nicholas R Latimer, et al.
Statistical Methods in Medical Research
|
April 27, 2016
Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study
Nicholas R Latimer, Keith R Abrams, Paul C Lambert, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 7, 2019
Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study
Helen Bell Gorrod, Nicholas R Latimer, Doris Damian, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 22, 2020
Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting
Thomas R Sullivan, Nicholas R Latimer, Jodi Gray, et al.
Advances in Therapy
|
November 9, 2019
Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods
Helen Bell Gorrod, Nicholas R Latimer, Doris Damian, et al.
MDM Policy & Practice
|
June 15, 2026
Evaluating the Impact of Different Natural History Modeling Methods on Cost-Effectiveness Decisions: A Case Study in Duchenne Muscular Dystrophy
Jonathan Broomfield, Keith R Abrams, Michael J Crowther, et al.
Page
of 5